整理 | GLP1减重宝典内容团队Altimmune, Inc.公司今日公布了其候选药物pemvidutide在代谢相关脂肪性肝炎(MASH)治疗中IMPACT 2b期临床试验的积极初步结果。然而,其疗效令投资人失望,股价一夜之间腰斩。本次试验共招募了212名经活检确诊为MASH并处于F2/F3纤维化阶段的受试者,涵盖有糖尿病与无糖尿病人群。试验将受试者按1:2:2比例随机分配,分别接受每周...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.